ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection
ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection
ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection

Frequently Asked Questions

Get quick answers about our diagnostic solution and partnership opportunities.

General

ErlySign is a non-invasive saliva-based diagnostic platform designed to detect oral cancer in its earliest stages.

This is a semi quantitative test in which we check for biomarkers in one’s saliva sample to assess the risk of pre cancerous conditions .The results can be quantified as Low - Moderate - High depending on the assessment.

No this is an early detection test and is meant to assess the risk of oral precancerous conditions and its ongoing or future development. This test is not meant to diagnose the cancer.Only Biopsies can confirm the cancer.

Individuals with high-risk factors like tobacco or alcohol use, poor oral hygiene, or family history of cancer are ideal candidates.

The kit has shown 98% sensitivity and 95% specificity, validated in clinical research.

From saliva sample to result, the process takes just 30–45 minutes.

Yes, ErlySign is expanding through partnerships with hospitals, diagnostic labs, and dental clinics across urban and rural India.

Product

The current kit detects biomarkers associated with oral cancer, with future versions screening for up to five cancer types.

Absolutely. The procedure is completely non-invasive — no needles, no surgery — just a simple saliva sample.

Currently, the test is offered through certified partner clinics and labs, with plans for at-home versions under development.

ErlySign offers early-stage detection at lower cost, without the pain or delays of biopsies, PET scans, or advanced imaging.

Your care provider will guide you through next steps, including referrals, further testing, or monitoring — all designed to act fast.

Partners

We welcome hospitals, diagnostic labs, and dental clinics to join our mission for early detection.

Partners gain access to cutting-edge diagnostics, increase patient trust, and open new revenue streams with minimal effort.

No major setup is needed. The test is designed to be plug-and-play and works even in low-resource settings.

Submit the Partner With Us form on our website and our team will get in touch for onboarding and training.

Yes, the kit is portable, does not need refrigeration, and is ideal for mass screening in rural outreach programs.

Still have any questions?

Can’t find the answer you’re looking for? Please connect with our friendly team.

Get Started with ErlySign

Fill in your details to explore how your clinic, lab, or hospital can integrate saliva-based early detection effortlessly.